For example, Carbone et al. found that BM-derived myeloma tumor cells from early clinical stage MM patients express low levels of the NK cell inhibitory ligand, MHC class I and high expression of the NKG2D ligands, MHC class I polypeptide–related sequence A (MICA) and MICB, but tumors from later-stage disease had the opposite expression pattern and were less susceptible to NK cell cytotoxicity [21]. Here, KLRK1 is linked to Miyoshi myopathy.